Myanmar Health Sciences Research Journal
Original Article:
The Korean Journal of Parasitology 2020; 58(3): 217-227.
Published online: June 26, 2020

Factors Influencing Compliance on Mass Drug Administration for Elimination of Lymphatic Filariasis in Mawlamyaing Township, Mon State

Nilar Aye Tun, Swe Zin Linn, Su Thet Mon Thein, Chan Nyein Aung, Min Thu, Thura Htun & Khaing Lay Mon

Myanmar Health Sciences Research Journal, Vol. 32, No. 1, 2020


Lymphatic filariasis is one of the negligible tropical diseases. This study aims to determine the factors that influence the Mass Drug Administration (MDA) compliance for lymphatic filariasis elimination. A cross-sectional analytical study was carried out in urban area of Mawlamyaing Township, Mon State during April and May 2018. The study population was the most responsible person of the household (index person), those over 18 years old, living in Mawlamyaing Township. In this study, a total of 261 households were included. Index person of each household was asked with structured questionnaires. Based on the information provided by each index person, there were 1093 eligible persons to take MDA in these 261 households whereas the majority (75.1%) of eligible people took MDA. The age of the participants ranged from 18 years to 85 years with the mean (±SD) age of 44.5(±13.3). Nearly two-thirds of respondents (65.9%) were Bamar where 80.5% of the index persons were female. The median monthly family income of the respondents was 250,000 kyats with inter-quartile range (150,000-300,000). Main reason for non-compliance was fear of side effects. Almost all respondents had correct knowledge about filariasis prevention. Attitude scores ranged from minimum 7 to maximum 28 with score of 7 to 20 regarded as poor attitude and score of 21 to 28 as good attitude; over half of the participants scored >20 marks for attitude. Association between race, knowledge and attitude of  index persons and compliance of family members on MDA are statistically significant.

Go to : Goto




Lymphatic filariasis is one of the neglected tropical diseases leading to the fourth most common cause of disability globally. It mainly damages the lymphatic system, causing the abnormal enlargement of body parts, causing pain, severe disability and social stigma.1 Approximately 120 million people were already infected worldwide. It is also estimated that 1.3 billion people in more than 80 countries have been living in filariasis endemic area. The South-East Asia Region (SEAR) accounts for two-thirds of the world’s filariasis endemic population, being the highest burden of lymphatic filariasis among the six WHO Regions. The nine lymphatic filariasis endemic countries in the SEAR are: Bangladesh, India, Indonesia, Maldives, Myanmar, Nepal, Sri Lanka, Thailand and Timor-Leste.2 In 2000, WHO launched the Global Program to Eliminate Lymphatic Filariasis (GPELF) setting the goal to eliminate lymphatic filariasis as a public health problem by the year 2020.1 The WHO recommended Mass Drug Administration (MDA) as preventive chemotherapy strategy for lymphatic filariasis elimination as the transmission cycle can be interrupted when MDA is conducted annually for 4-6 years with effective coverage in filarial endemic area. MDA program is intended to involve all eligible persons living in all endemic areas with one of the following 3 regimens of safe, anthelminthic medicines: diethylcarbamazine plus albendazole (DA) in entire at-risk population; ivermectin plus albendazole (IA) in areas co-endemic for onchocerciasis; or albendazole preferably twice yearly in areas co-endemic for loiasis.3

In 2000, Myanmar had initiated WHO collaborative Global Programme to Eliminate Lymphatic Filariasis (GPELF) and Ministry of Health established the National Plan to Eliminate Lymphatic Filariasis (NPELF). This strategy was intended to eliminate lymphatic filariasis in 2020 (i.e. less than 1/1000 population) through Mass Drug Administration (MDA) using 2 drugs: Diethylcarbamazine and Albendazole (DA). MDA was started in 10 townships in Magwe Region as a pilot project in 2001.4

The MDA campaign was introduced in 2013 and designed for 5 years. Pregnant women, children under 2 year-old, and the severely ill persons are ineligible for MDA administration.3

In 2016, Myanmar became one of the countries where MDA program was scaled up to all endemic districts. According to the MOHS, 31 million people were reported to receive MDA by 36 implementation units in 2016, achieving 100% geographical coverage, 85% program coverage and 88.5% national coverage.5

This study was conducted in Mawlamyaing township, Mon State. This is because Mon State was at the second lowest MDA compliance (94.3%) in Myanmar and Mawlamyaing was the lowest among all townships of Mon State with 88.4%.5

In fact, the success of a MDA program depends on the achievement of high coverage and good compliance in each of  the implementation units. This study was mainly conducted to explore the factors that influence the compliance on MDA for lymphatic filariasis elimination. In this study, knowledge and attitudes on lymphatic filariasis among the study population, proportion of drug compliance among the residents and the reasons for not taking the MDA drugs were identified as well. By determining these factors, the ways to achieve elimination of lymphatic filariasis could be explored.

Go to : Goto




Study design

A community-based cross-sectional analytical study was conducted.

Study area and periods

The study was conducted during April and May 2018. Mon State was purposively selected because it was the second lowest compliance on MDA program in 2016.5 The reason for conducting this study in Mawlamyaing Township was that it had the lowest MDA compliance in 2016 among all the townships of Mon State.5


Required sample size for this study was determined by using the proportion of good compliance on MDA (63.1%) from a 2016 study done in Mandalay Region by  Ei Ei Win, at 95% confidence interval (z=1.96).6, 7 The minimum required sample size was 250. In order to compensate information loss to incomplete data, a total of 261 participants were interviewed in this study. In order to participate in this study, the study population must be at least 18 years old and had been residing in Mawlamyaing Township for at least 6 months. Critically ill people, either physically or mentally, were excluded from this study. Those over 18 years old as well as the most responsible person of each household, so called the index person were given informed consent. Once the willing participants were well-informed of the study purpose and signing the written informed consent, they were interviewed by using semi-structured questionnaires.

There are thirty-two wards in urban area of Mawlamyaing Township. Five wards of Mawlamyaing Township were selected by simple random sampling choosing fifty-two households from each ward. Then, house-holds were selected by systematic sampling method by using sampling frame. When the selected household was not occupied by the index person at that time, the right adjacent household was selected.

Data collection methods and tools

Data was collected by face to face interview with pretested structured questionnaires in Myanmar language. The questionnaires were developed from literature review.6, 10, 11 All the questions were pretested on 24 respondents in Yangon, checking the appropriateness for the study and convenience for the participants to answer. It was a total of 30 minutes required for each participant to answer all the questionnaires.

Data management and statistical analysis

After data collection, data checking was done daily for completeness and consis-tencies. Data entry was done by SPSS 22.0 software and after checking the missing data and inconsistencies, exploratory data analysis was performed. Then, for descript-tive data analysis, frequency and percentage was calculated for categorical variables, mean (standard deviation) for normally istributed continuous variables, and median (inter quartile range) for continuous data without normal distribution. For statistical analysis, Chi-square test was used to examine the associated factors on MDA compliance. A p value of less than 0.05 was set as a cut-off point for statistically significant association.

Ethical consideration

Before data collection, ethical clearance was taken from the Institutional Review Board of University of Public Health with UPH-IRB (2018/MPH-G/3). The individual respondents participated in this research voluntarily giving consent by signing consent form
with the approval signs.
Names of the participants were not included in the data collection. All the data were kept under strict confidentiality and will be destroyed one year after the research. All data files were protected by password.





In this study, Bamar respondents showed higher compliance (87.2%) compared to Mon (74%) and other races (74.4%).

The overwhelming majority of 88.1% and 96.5% of the respondents had correct knowledge about transmission and pre-vention of filariasis, which were higher than previous studies done in Chan-Aye-Thar-San Township in 2016 (66.4% and 80%), and in India in 2013 (15.3% and 17.6%).6, 8 Moreover, most (81.9%) of respondents mentioned the healthcare providers as the source of information in this study with half (50%) and 22%, in Mandalay and Peninsular Malaysia studies, respectively.6, 9 It was also observed that almost all respondents (99.9%) were aware of the MDA program, which is far higher than that of Peninsular Malaysia study (35.2%).9 This study population had better knowledge and awareness of the MDA program when compared with the previous studies done in India, 2013 and in Mandalay, 2016.6, 8 This was because it was three months prior to our study that the MDA drug distribution had been carried out in Mawlamyaing township.

On the other hand, regarding the non-eligible criteria for taking MDA, well over one-third (37.2%) of the participants answered pre-gnancy and a quarter (24.9%) of the parti-cipants knew under 2 years children as non-eligible for taking MDA. Therefore, health care providers should educate to the whole community about the contraindications of the MDA drugs.

In this study, 91.4% of the respondents  with high knowledge score (>16 marks) had compliance. Likewise, in the studies done in Magway and in Sagaing, these studies consistently showed that respondents with high knowledge score consumed or accepted the drugs more than those respondents with low knowledge score did.10, 11 Furthermore, there was also significant association between attitude score of index person and com-pliance of MDA drugs by their eligible family members. Similarly, attitude was associated with MDA compliance in the previous studies done in Magway and in Indonesia.10, 12 On account of this, when the index persons had better knowledge and greater attitude level towards lymphatic filariasis and MDA program, they were more likely to encourage his or her family. In that way, compliance is improved.

When the compliance status of household on MDA was observed, it is nearly one-fifth of our study population that no household member among the households with eligible persons took MDA. All of the household members among the 60.2% of households with eligible persons took MDA in our study. The compliance rate from previous studies were 63.1% among 263 individuals in Chan-Aye-Thar-San Township, 70.1% among 603 individuals in India study, and 85.3% among 2859 individuals in Egypt study.6, 8, 13

The reason why the compliance status of this study varied from other studies could be due to geographical difference and different socio-demographic characteristics of study population. Unlike the other studies, the compliance status in this study was calculated at the household level based on the answers from the index persons, not from each individual household member. Perhaps this could lead to information bias.

Compliance status of the whole Mawlamyaing Township was reported to be 94.6%, however, this study revealed compliance rate as 75.1% which is the interviewed data.5 Although MOHS reported data on compliance of Mawlamyaing included both urban and rural areas, this study was carried out only in urban area. This could be root cause of different results. When the reasons for non-consumption of MDA were explored, fear of side effects and lack of detailed explanation about how and who should take MDA, and no information where to seek help if any adverse effect occurs were emphasized as the fundamental causes of their non-compliance. Some reasons also include travelling (not at home at the time of drug distribution) and unwillingness to take. Similar reasons were also found in India, in Sri Lanka.8, 14

Interestingly, very few people in this study stated that they were dictated by the most powerful family member not to take the MDA drugs. Thus, healthcare providers should educate the importance and advantages of taking MDA, the major and minor side effects of MDA, information about proper care for those who suffered side effects.


The study noted that the relationship between knowledge and compliance of MDA drugs, attitude level and MDA compliance were statistically significant. With regard to reason for non-compliance  of MDA drugs, it was indicated that fear of side effects as the main reason. Since the study was done only in urban area of Mawlamyaing Township, Mon State, similar studies are required to be carried out in other states and regions to identify the barriers to MDA compliance among the community for the elimination of lymphatic filariasis.

Go to : Goto



We would like to express our sincerest gratitude and special respect to our rector, professors, teachers and supervisors at the University of Public Health, Yangon for their valuable advices and kind supervision on our study. We gratefully acknowledge the local authorities, responsible personnel, and the participants from Mawlamyaing Township. This research was funded by DMR external grant 70/2018.

Go to : Goto

Competing interests

The authors declare that they have no competing interests.

Go to : Goto



1.    World Health Organization. Lymphatic Filariasis: Fact Sheet. [Internet]. 2017. Available from: [ ]

2.    World Health Organization. Elimination of Lymphatic Filariasis in South East Asia Region: Report of the Ninth Meeting of the Regional Programme Review Group (RPRG) Yangon, Myanmar, 30 April–1 May 2012.  [Internet]. 2011. Available from [Accessed 6 February 2018]. [ handle/10665/204988.]

3.     World Health Organization. Guideline: Alternative Mass Drug Administration Regimens to Eliminate Lymphatic Filariasis. [Internet]. 2017. [Accessed 6 February 2018]. Available from: [ iris/handle /10665/259381.]

4.     World Health Organization. MDA for Control of Lymphatic Filariasis Campaign 2013 in Myanmar. [Internet]. 2013. Available from: [Accessed 11 March 2018]. <http://www. myanmar/ areas/ malaria_ mdacontrol/en/

5.    National Malaria Control Programme. Report of Mass Drug Administration Coverage by Implementation Units. National Malaria Control Programme, MOHS, 2016

6.     Ei Ei Win. Knowledge on lymphatic filariasis and attitude and compliance on mass drugs administration in Chan-Aye-Thar-San Township, Mandalay. [MPH thesis]. University of Public Health: Yangon; 2016.

7.      Daniel WW & Cross CL. Biostatistics: A Foundation for Analysis in the Health Sciences. Tenth Ed., USA, John Wiley & Sons, 2013; p.191-192.

8.     Roy RN, Sarkar AP, Misra R, Chakroborty A, Mondal TK & Bag K. Coverage and awareness of and compliance with mass durg administration for elimination of lymphatic filariasis in Burdwan District, West Bengal, India. Journal of Health, Population and Nutrition 2013; 31(2): 171-177.

9.     Al-Abd NM, Nor ZM, Ahmed A, Al-Adhroey AH, Mansor M & Kassim M. Lymphatic filariasis in Peninsular Malaysia: A cross-sectional survey of the knowledge, attitudes, and practices of residents. Parasite & Vectors 2014; 7(1):  545.

10.   Aung Tint. Community acceptance and compliance on mass drug administration for filarisis in urban Magway. [MMedSc thesis]. Institute of Medicine: Mandalay; 2002.

11.    Aung Win. Knowledge on filariasis, attitude and acceptance on mass drug administration for filariasis in Sagaing Township, Sagaing Division. [MMedSc thesis]. University of Medicine: Mandalay; 2007.

12.   Krental A, Fisher P, Manoempil P, Supali T, Servais G & Ruckert P. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia. Tropical Medicine & International Health 2006; 11(11): 1731-1740.

13.   Abd Elaziz KM, El-Setouhy Bradley MH, Ramzy RM & Weil GJ. Knowledge and practice related to compliance with mass drug administration during the Egyptian National Filariasis Elimination Program. The American Journal of Tropical Medicine and Hygiene 2013; 89(2): 260-264.

14.  Weerasooriya MV, Yahathugoda CT, Wickramasinghe D, Gunawardena KN, Dhamadasa RA, Vidanapathirana KK, et al. Social mobilization, drug coverage and compliance and adverse reactions in a Mass Drug Administration (MDA) Programme for the elimination lymphatic filariasis in Sri Lanka. Filaria Journal 2007; 6(1): 11.

Vision : Achieving a healthier nation through application of research findings          Mission Statement : To Develop and promote solutions to the major health problems of Myanmar